Compare Abeona Therapeutics Inc (ABEO) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Manulife Financial Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Manulife Financial Corporation trades at $41.08 (market cap $68.99B). The key difference: Manulife Financial Corporation is far larger — about 184.8× Abeona Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MFC | |
|---|---|---|
Market Cap | $373.32M | $68.99B |
Sector | Health | Financials |
52-Week High | $7.23 | $41.40 |
52-Week Low | $4.17 | $29.90 |
Enterprise Value | $228.22M | $65.55B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Manulife Financial (MFC) trades at $41.40, up 0.53% today, with a bullish technical signal from moving averages and strong analyst support (57% buy ratings). Recent Q1 2026 earnings missed expectations, but revenue grew to $53.01B in 2025, with net income of $5.78B. The company maintains a solid dividend, with a $0.49 payment scheduled for June 2026, and has demonstrated consistent operational cash flow growth, reaching $32.11B in 2025.
MFC's outlook is positive due to its AI initiatives and Asia growth, but risks include regulatory scrutiny and Q1 earnings miss. The stock's P/E of 16.92 and ROE of 13.14% suggest reasonable valuation, though investors should monitor debt levels and competitive pressures in insurance markets for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
